These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 31359367)

  • 1. Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.
    Kalra S; Das AK; Sahay RK; Baruah MP; Tiwaskar M; Das S; Chatterjee S; Saboo B; Bantwal G; Bhattacharya S; Priya G; Chawla M; Brar K; Raza SA; Aamir AH; Shrestha D; Somasundaram N; Katulanda P; Afsana F; Selim S; Naseri MW; Latheef A; Sumanatilleke M
    Diabetes Ther; 2019 Oct; 10(5):1645-1717. PubMed ID: 31359367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation.
    Hanif W; Ali SN; Bellary S; Patel V; Farooqi A; Karamat MA; Saeed M; Sivaprasad S; Patel K; Khunti K
    Diabet Med; 2021 Apr; 38(4):e14497. PubMed ID: 33301625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies.
    Neumiller JJ
    Med Clin North Am; 2015 Jan; 99(1):107-29. PubMed ID: 25456646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future.
    Kalra S; Baruah MP; Sahay RK; Unnikrishnan AG; Uppal S; Adetunji O
    Indian J Endocrinol Metab; 2016; 20(2):254-67. PubMed ID: 27042424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.
    Baruah MP; Kalra S; Unnikrishnan AG; Raza SA; Somasundaram N; John M; Katulanda P; Shrestha D; Bantwal G; Sahay R; Latt TS; Pathan F
    Indian J Endocrinol Metab; 2011 Apr; 15(2):75-90. PubMed ID: 21731863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
    Lovshin JA
    Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
    Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
    Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes.
    Yabe D; Seino Y
    Expert Rev Endocrinol Metab; 2014 Nov; 9(6):659-670. PubMed ID: 30736202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes.
    Edwards KL; Minze MG
    Core Evid; 2015; 10():11-21. PubMed ID: 25657615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
    Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
    Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.